therapeutic action: fungal burden reduction

Dectin-1 and dectin-2 drive protection against Sporothrix brasiliensis in experimental sporotrichosis

mycolabadmin

Researchers studied how the body fights a dangerous fungus called Sporothrix brasiliensis that causes sporotrichosis. They found that two immune receptors called dectin-1 and dectin-2 are crucial for protecting against this infection in mice. Surprisingly, these receptors work by activating killer immune cells and controlling regulatory immune cells, rather than through the typical immune response pathway scientists expected.

Read More »

Conjugation of a Cryptococcus neoformans-derived metalloprotease to antifungal-loaded PLGA nanoparticles treats neural cryptococcosis in an in vitro model

mycolabadmin

Researchers developed special nanoparticles that can cross the protective barrier surrounding the brain by using a protein from a fungal infection. These nanoparticles are loaded with an antifungal drug and can effectively treat cryptococcal brain infections in laboratory tests. This approach offers a new way to deliver medicines to the brain without invasive procedures, potentially helping patients with serious brain infections that are currently difficult to treat.

Read More »

Low Antigen Titre Disseminated Cryptococcosis in Immunocompromised Hosts: Two Challenging Case Reports

mycolabadmin

Two patients with weakened immune systems developed serious fungal blood infections from Cryptococcus despite having unusually low levels of fungal markers in their blood. One was a kidney transplant patient and the other had HIV. Neither showed signs of brain infection, which is unusual for this disease. Both were successfully treated with aggressive antifungal medications once blood cultures confirmed the disseminated infection.

Read More »

Conjugation of a Cryptococcus neoformans-derived metalloprotease to antifungal-loaded PLGA nanoparticles treats neural cryptococcosis in an in vitro model

mycolabadmin

Researchers developed tiny nanoparticle carriers coated with a fungal enzyme that helps them cross the protective barrier around the brain. These particles were loaded with an antifungal drug to treat brain infections caused by Cryptococcus neoformans. In laboratory tests, the Mpr1-coated particles successfully penetrated the blood-brain barrier better than regular nanoparticles and were more effective at killing the fungal cells.

Read More »

A case of Blastomyces helicus pneumonia in a dog from a non-endemic region: diagnostic challenges and successful treatment outcome

mycolabadmin

A dog developed severe pneumonia from an emerging fungal infection called Blastomyces helicus after traveling to Utah and Idaho. Initial blood tests incorrectly suggested a different fungus, but laboratory culture and genetic testing identified the true culprit. The dog was successfully treated with an antifungal medication called itraconazole and made a complete recovery with careful monitoring over 6 months.

Read More »

Immunomodulatory activity of Pleurotus pulmonarius crude extract to human monocyte against Cryptococcus neoformans

mycolabadmin

This research shows that an extract from the Phoenix oyster mushroom (Pleurotus pulmonarius) can boost the body’s immune cells to fight dangerous fungal infections caused by Cryptococcus neoformans. When immune cells are pre-exposed to this mushroom extract and then encounter the fungus, they become more effective at killing it through increased production of immune-signaling molecules and reactive oxygen species. This natural supplement approach offers a promising alternative to traditional antifungal drugs, which often have significant side effects and can lead to drug resistance.

Read More »

Efficacy of SCY-247, a Second-generation Triterpenoid Antifungal, in Three Murine Models of Invasive Fungal Infections

mycolabadmin

Researchers tested a new antifungal drug called SCY-247 in mice to treat serious fungal infections. The drug was given orally and showed strong effectiveness against common fungal infections caused by Candida and Rhizopus species, including strains resistant to current treatments. Higher doses of the drug produced better results, and the drug effectively concentrated in the organs most affected by fungal infections.

Read More »
Scroll to Top